P R Harrigan
Overview
Explore the profile of P R Harrigan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wheeler J, Chan S, Harrigan P, Becker M, Kasper K, Keynan Y
Int J STD AIDS
. 2018 Mar;
29(5):520-522.
PMID: 29513131
No abstract available.
2.
Jacka B, Bray B, Applegate T, Marshall B, Lima V, Hayashi K, et al.
J Viral Hepat
. 2017 Jul;
25(1):28-36.
PMID: 28719060
This study estimated latent classes (ie, unobserved subgroups in a population) of people who use drugs in Vancouver, Canada, and examined how these classes relate to phylogenetic clustering of hepatitis...
3.
Rocheleau G, Brumme C, Shoveller J, Lima V, Harrigan P
Clin Microbiol Infect
. 2017 Jun;
24(2):185-191.
PMID: 28652115
Objectives: We aim to identify long-term trends in HIV drug resistance before and after combined antiretroviral therapy (cART) initiation. Methods: IAS-USA (2015) mutations were identified in 23 271 HIV protease-reverse...
4.
St-Jean M, Harrigan P, Sereda P, Montaner J, Lima V
HIV Med
. 2016 Oct;
18(5):342-353.
PMID: 27704659
Objectives: The World Health Organization (WHO)'s HIV drug resistance (HIVDR) early warning indicators (EWIs) measure antiretroviral therapy (ART)-site factors associated with HIVDR prevention, without HIVDR laboratory testing. We assessed the...
5.
Gonzalez-Serna A, Swenson L, Watson B, Zhang W, Nohpal A, Auyeung K, et al.
Clin Microbiol Infect
. 2016 Sep;
22(12):1004.e9-1004.e16.
PMID: 27585940
Suboptimal untimed plasma drug levels (UDL) have been associated with lower rates of virologic suppression and the emergence of drug resistance. Our aim was to evaluate whether UDL among patients...
6.
Lapointe H, Dong W, Lee G, Bangsberg D, Martin J, Mocello A, et al.
Antimicrob Agents Chemother
. 2015 Aug;
59(11):6824-33.
PMID: 26282425
Limited access to HIV drug resistance testing in low- and middle-income countries impedes clinical decision-making at the individual patient level. An efficient protocol to address this issue must be established...
7.
Chui C, Dong W, Joy J, Poon A, Dong W, Mo T, et al.
J Clin Microbiol
. 2015 Jul;
53(9):2942-50.
PMID: 26135875
Persons with hepatitis C virus (HCV) genotype 1a (GT1a) infections harboring a baseline Q80K polymorphism in nonstructural protein 3 (NS3) have a reduced virologic response to simeprevir in combination with...
8.
Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan P, Marshall B, et al.
Hepatology
. 2014 Jul;
60(5):1571-1580.
PMID: 25042607
Unlabelled: Little is known about factors associated with hepatitis C virus (HCV) transmission among people who inject drugs (PWID). Phylogenetic clustering and associated factors were evaluated among PWID in Vancouver,...
9.
Payne R, Branch S, Kloverpris H, Matthews P, Koofhethile C, Strong T, et al.
J Virol
. 2014 Feb;
88(9):4668-78.
PMID: 24501417
Unlabelled: HLA-B*57:01 and HLA-B*57:03, the most prevalent HLA-B*57 subtypes in Caucasian and African populations, respectively, are the HLA alleles most protective against HIV disease progression. Understanding the mechanisms underlying this...
10.
Gonzalez-Serna A, Min J, Woods C, Chan D, Lima V, Montaner J, et al.
Clin Infect Dis
. 2014 Jan;
58(8):1165-73.
PMID: 24429436
Background: Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50-999 copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are few or no data available demonstrating that HIV-1...